​

Some breakthroughs don’t start with a grant or a roadmap — they start with a question no one expects to matter. For JB, that moment was a cold email from a biologist he’d never met, asking if he could synthesize a molecule “when you’re back in Munich.” That simple ask pulled a young chemist out of the fume hood and into the messy, electrifying world of live-cell biology. What followed — a trip to London, confocal imaging marathons, and a partnership built on trust and c

Most GPCR programs don’t fail because of weak molecules—they fail because biology behaves differently than the assay implied. This week’s feature goes straight to the foundation: how system-level GPCR thinking protects discovery teams from the costly misinterpretations that derail programs. If your work touches GPCR pharmacology, these insights aren’t optional—they’re essential.

The Cost of Confusion Let’s be honest. Most biotech pitches don’t fail because the science is weak. They fail because the story is unclear. 👉 A confusing pitch doesn’t just slow down progress. It silently shuts down opportunity. You might still get the meeting. You might still get a few questions. But behind the polite nods, your audience is checking out. Here’s the uncomfortable truth: 👉 People make up their minds in the first few seconds. If your pitch doesn’t immediately

Discovery programs rarely fail because a molecule “did nothing.” They fail because a molecule behaved exactly as the underlying system allowed—amplified, buffered, redirected, or reshaped by layers of receptor biology that weren’t accounted for. The October 30th AMA with Dr. Kenakin highlighted a fundamental truth: GPCR systems do not offer stable, proportional input–output relationships. Receptor density, constitutive activity, coupling efficiency, local signaling archit

Science used to reward the lone genius—the first author who “drove the project,” the PI whose name defined a field. But the problems we face today—metabolic disease, obesity, GPCR signaling complexity—are too layered, too multidimensional, too systemic for single-discipline solutions. As Hodson put it, the work he leads now would be impossible without partnerships. Whether it's human genetics, imaging platforms, peptide chemistry, or neural metabolic mapping—every piece re